Vera Belgers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vera Belgers has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Linda Douw
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, de Boelelaan 1108, Amsterdam, the Netherlands
10 shared publications - Martin Klein
Department of Medical Psychology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
9 shared publications - Philip Charles De Witt Hamer
Department of Neurosurgery, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands
6 shared publications - Jantine Geertruida Röttgering
Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, The Netherlands
5 shared publications Jantine G Röttgering
Department of Medical Psychology, Cancer Center Amsterdam, Brain Tumor Center, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam
4 shared publicationsJohanna M Niers
Department of Neurology, Cancer Center Amsterdam, Brain Tumor Center, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam
4 shared publications
Latest Publications
- Open Access
- 22 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (5) , 1023-1024
Cannabidiol for anxiety and depressive symptoms in primary brain tumors: Results from an early-terminated, placebo-controlled, crossover randomized clinical trial
- 22 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (5) , 1023-1024
Open AccessCannabidiol for anxiety and depressive symptoms in primary brain tumors: Results from an early-terminated, placebo-controlled, crossover randomized clinical trial
- Open Access
- 9 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 693-703
Bayesian adaptive randomized trial of blended cognitive behavioral therapy for severe fatigue in stable diffuse glioma
Abstract Background: While severe fatigue is common in patients with diffuse glioma, no evidence-based treatment is currently available. The objective of this RCT was to evaluate the efficacy of blended cognitive behavioral therapy (bCBT) for severe fatigue. Methods: Severely fatigued patients (Checklist Individual Strength, fatigue-severity subscale [CIS-fatigue] ≥ 35) with diffuse glioma and stable disease were randomized to 12 weeks of bCBT or a waiting list condition (WLC). The primary endpoint was fatigue severity 2 weeks after intervention. This Bayesian adaptive trial included prespecified interim analyses for efficacy at n = 40, 50, 60, 70, and 80. Secondary outcomes—health-related quality of life (HRQoL), anxiety, future uncertainty, and depression—were assessed at 2 and 12 weeks after intervention. Results: The trial was stopped for efficacy at the first interim analysis. Of 47 patients randomized, 40 patients reached the primary endpoint (mean age 53 years, 47% female). The posterior probability that CIS-fatigue scores were lower with bCBT than with WLC was 99.94%, with a large standardized effect size (Cohen’s d) of 1.12 [95% CI: 0.43–1.81]. At 2 weeks after intervention, 68% of patients were no longer severely fatigued after bCBT, compared to 24% in WLC. At 12 weeks follow-up, fatigue was still significantly lower in the bCBT group compared to WLC (d = 1.22). bCBT also demonstrated beneficial effects (d = 0.42-1.19) on anxiety, HRQoL, and future uncertainty. Conclusions: bCBT significantly reduces fatigue and improves anxiety and HRQoL in patients with diffuse glioma. These findings enable evidence-based supportive care strategies for reducing fatigue and enhancing HRQoL in this population.
- 9 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 693-703
Open AccessBayesian adaptive randomized trial of blended cognitive behavioral therapy for severe fatigue in stable diffuse glioma
Abstract Background: While severe fatigue is common in patients with diffuse glioma, no evidence-based treatment is currently available. The objective of this RCT was to evaluate the efficacy of blended cognitive behavioral therapy (bCBT) for severe fatigue. Methods: Severely fatigued patients (Checklist Individual Strength, fatigue-severity subscale [CIS-fatigue] ≥ 35) with diffuse glioma and stable disease were randomized to 12 weeks of bCBT or a waiting list condition (WLC). The primary endpoint was fatigue severity 2 weeks after intervention. This Bayesian adaptive trial included prespecified interim analyses for efficacy at n = 40, 50, 60, 70, and 80. Secondary outcomes—health-related quality of life (HRQoL), anxiety, future uncertainty, and depression—were assessed at 2 and 12 weeks after intervention. Results: The trial was stopped for efficacy at the first interim analysis. Of 47 patients randomized, 40 patients reached the primary endpoint (mean age 53 years, 47% female). The posterior probability that CIS-fatigue scores were lower with bCBT than with WLC was 99.94%, with a large standardized effect size (Cohen’s d) of 1.12 [95% CI: 0.43–1.81]. At 2 weeks after intervention, 68% of patients were no longer severely fatigued after bCBT, compared to 24% in WLC. At 12 weeks follow-up, fatigue was still significantly lower in the bCBT group compared to WLC (d = 1.22). bCBT also demonstrated beneficial effects (d = 0.42-1.19) on anxiety, HRQoL, and future uncertainty. Conclusions: bCBT significantly reduces fatigue and improves anxiety and HRQoL in patients with diffuse glioma. These findings enable evidence-based supportive care strategies for reducing fatigue and enhancing HRQoL in this population.
- Open Access
- 27 August 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (12) , 3250-3259
Distinct and reproducible neurocognitive profiles in stable diffuse glioma: A data-driven approach to understanding cognitive heterogeneity
Background: Glioma patients often exhibit neurocognitive deficits across multiple domains, yet studies typically assess these impairments separately. This study explores aggregated neurocognitive functioning (NCF), identifying distinct profiles and their clinical correlates. Methods: NCF in glioma patients with stable disease (≥ 2 months after treatment without clinical or radiological progression) was assessed across five domains: attention, information processing speed, verbal memory, working memory, and flexibility. We used hierarchical cluster analysis to distinguish neurocognitive profiles and replicated these profiles in an independent glioma cohort. Associations between neurocognitive profiles and clinical characteristics were examined using multinomial logistic regression. Results: Four distinct neurocognitive profiles were identified in both the study (N = 108) and the validation cohort (N = 185): a preserved, memory, processing/attention, and multi-domain profile. In both cohorts, 40% of patients exhibited impaired NCF, with deficits in at least one domain observed in 44% in the study cohort and 38% in the validation cohort. In the study cohort, tumor hemisphere and prior treatment with radiotherapy or combined radio- and chemotherapy were associated with processing/attention and multi-domain profiles. In both the cohorts, the multi-domain profile showed a weak association with self-perceived NCF. No other significant associations with patient, tumor, or treatment characteristics were observed. Conclusions: NCF in glioma patients can be classified into four reproducible neurocognitive profiles. Importantly, concurrent problems in NCF are highly prevalent. Neurocognitive profiles are associated with tumor laterality, previous oncological treatment, and self-perceived NCF, but not with other clinical characteristics.
- 27 August 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (12) , 3250-3259
Open AccessDistinct and reproducible neurocognitive profiles in stable diffuse glioma: A data-driven approach to understanding cognitive heterogeneity
Background: Glioma patients often exhibit neurocognitive deficits across multiple domains, yet studies typically assess these impairments separately. This study explores aggregated neurocognitive functioning (NCF), identifying distinct profiles and their clinical correlates. Methods: NCF in glioma patients with stable disease (≥ 2 months after treatment without clinical or radiological progression) was assessed across five domains: attention, information processing speed, verbal memory, working memory, and flexibility. We used hierarchical cluster analysis to distinguish neurocognitive profiles and replicated these profiles in an independent glioma cohort. Associations between neurocognitive profiles and clinical characteristics were examined using multinomial logistic regression. Results: Four distinct neurocognitive profiles were identified in both the study (N = 108) and the validation cohort (N = 185): a preserved, memory, processing/attention, and multi-domain profile. In both cohorts, 40% of patients exhibited impaired NCF, with deficits in at least one domain observed in 44% in the study cohort and 38% in the validation cohort. In the study cohort, tumor hemisphere and prior treatment with radiotherapy or combined radio- and chemotherapy were associated with processing/attention and multi-domain profiles. In both the cohorts, the multi-domain profile showed a weak association with self-perceived NCF. No other significant associations with patient, tumor, or treatment characteristics were observed. Conclusions: NCF in glioma patients can be classified into four reproducible neurocognitive profiles. Importantly, concurrent problems in NCF are highly prevalent. Neurocognitive profiles are associated with tumor laterality, previous oncological treatment, and self-perceived NCF, but not with other clinical characteristics.
- Open Access
- 31 July 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (1) , 149-161
Self-reported physical functioning and physical fitness in glioma patients
Background: Knowledge about glioma patients’ physical functioning and physical fitness throughout the disease trajectory is limited. We analyzed self-reported functioning and fitness in a large sample of glioma patients preoperatively and after primary treatment. Methods: We used the physical functioning subscale of the 36-Item Short Form Health Survey (SF36) and three questions about physical fitness from the Checklist of Individual Strength (CIS20). Scores were compared to age-, sex-, and education-matched population controls, preoperatively and after treatment. In patients with repeated assessments, changes over time were analyzed. Correlations between patient, disease, and treatment characteristics and functioning and fitness at both time points, and with change over time, were explored. Analyses were performed separately for World Health Organization grade II, III, and IV glioma. Results: Grade III patients had significantly lower functioning than controls, both preoperatively and after treatment, and declined over time. No significant differences with controls were found for grade II and IV patients, or for fitness. Grade II patients reported better functioning than grade III and IV preoperatively and better than grade III after treatment. Lower Karnofsky Performance Status was generally related to lower functioning and fitness, while older age, female sex, and lower education appeared in subgroup analyses. Age, neurological disabilities and tumor histology were associated with changes over time. Conclusions: Grade III glioma patients showed poorer functioning than population controls, which declined over time. Grade II patients reported better outcomes than the other subgroups, although individual variability was high. These findings highlight the need for personalized approaches addressing functioning and fitness in glioma.
- 31 July 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (1) , 149-161
Open AccessSelf-reported physical functioning and physical fitness in glioma patients
Background: Knowledge about glioma patients’ physical functioning and physical fitness throughout the disease trajectory is limited. We analyzed self-reported functioning and fitness in a large sample of glioma patients preoperatively and after primary treatment. Methods: We used the physical functioning subscale of the 36-Item Short Form Health Survey (SF36) and three questions about physical fitness from the Checklist of Individual Strength (CIS20). Scores were compared to age-, sex-, and education-matched population controls, preoperatively and after treatment. In patients with repeated assessments, changes over time were analyzed. Correlations between patient, disease, and treatment characteristics and functioning and fitness at both time points, and with change over time, were explored. Analyses were performed separately for World Health Organization grade II, III, and IV glioma. Results: Grade III patients had significantly lower functioning than controls, both preoperatively and after treatment, and declined over time. No significant differences with controls were found for grade II and IV patients, or for fitness. Grade II patients reported better functioning than grade III and IV preoperatively and better than grade III after treatment. Lower Karnofsky Performance Status was generally related to lower functioning and fitness, while older age, female sex, and lower education appeared in subgroup analyses. Age, neurological disabilities and tumor histology were associated with changes over time. Conclusions: Grade III glioma patients showed poorer functioning than population controls, which declined over time. Grade II patients reported better outcomes than the other subgroups, although individual variability was high. These findings highlight the need for personalized approaches addressing functioning and fitness in glioma.
- Open Access
- 23 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (4) , 714-722
Cannabis use among Dutch patients with a primary brain tumor
Background: Cancer patients commonly use cannabis to improve symptoms or for presumed anticancer effects. However, the extent and type of cannabis use among Dutch primary brain tumor patients, along with their motivations, remains unclear. This study aims to determine the prevalence of prior or current cannabis use in patients with a primary brain tumor, the type of cannabis used, their motivation, how they perceived the effects of the cannabis, and what adverse effects they noticed. Methods: We conducted a cross-sectional survey of adult primary brain tumor patients who visited the neuro-oncology outpatient clinic at Amsterdam UMC between August and October 2023. Results: Of 100 responding patients, 51% had ever used cannabis and 14% currently used cannabis. Of the total group, 19% currently or previously used cannabis for tumor-related reasons, including symptom relief (n = 14; 74%) and presumed effect on the tumor (n = 8; 42%), indicating that some patients used it for multiple therapeutic purposes. Patients favored cannabidiol (CBD) over Δ9-tetrahydrocannabinol (THC). Self-reported sleep, anxiety, worrying, and depressive symptoms most frequently improved due to cannabis use, and the most common self-reported adverse events included drowsiness, dry mouth, and dizziness. Conclusions: A considerable amount of primary brain tumor patients use cannabis, often for symptom relief or presumed antitumor effects. The user rate underscores a demand for clinical research into the therapeutic efficacy of cannabis, particularly concerning its impact on symptoms like sleep disturbances, depressive symptoms, and anxiety/worrying, as well as its tumor-inhibiting capabilities.
- 23 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (4) , 714-722
Open AccessCannabis use among Dutch patients with a primary brain tumor
Background: Cancer patients commonly use cannabis to improve symptoms or for presumed anticancer effects. However, the extent and type of cannabis use among Dutch primary brain tumor patients, along with their motivations, remains unclear. This study aims to determine the prevalence of prior or current cannabis use in patients with a primary brain tumor, the type of cannabis used, their motivation, how they perceived the effects of the cannabis, and what adverse effects they noticed. Methods: We conducted a cross-sectional survey of adult primary brain tumor patients who visited the neuro-oncology outpatient clinic at Amsterdam UMC between August and October 2023. Results: Of 100 responding patients, 51% had ever used cannabis and 14% currently used cannabis. Of the total group, 19% currently or previously used cannabis for tumor-related reasons, including symptom relief (n = 14; 74%) and presumed effect on the tumor (n = 8; 42%), indicating that some patients used it for multiple therapeutic purposes. Patients favored cannabidiol (CBD) over Δ9-tetrahydrocannabinol (THC). Self-reported sleep, anxiety, worrying, and depressive symptoms most frequently improved due to cannabis use, and the most common self-reported adverse events included drowsiness, dry mouth, and dizziness. Conclusions: A considerable amount of primary brain tumor patients use cannabis, often for symptom relief or presumed antitumor effects. The user rate underscores a demand for clinical research into the therapeutic efficacy of cannabis, particularly concerning its impact on symptoms like sleep disturbances, depressive symptoms, and anxiety/worrying, as well as its tumor-inhibiting capabilities.
- Open Access
- 16 December 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdae222
Impact of resection location on depressive symptoms following glioma surgery
Background: Glioma surgery aims to maximize tumor removal while preserving functional integrity. Functional outcome usually focuses on neurological and neurocognitive functions, but surgery may also affect mood regulation. We determined the occurrence of depressive symptoms after surgery and investigated associated factors, including preoperative depressive symptoms and the location of the resection. Methods: We included a single-center retrospective cohort of patients with supratentorial diffuse glioma (WHO grade 2–4) who underwent first-time surgical resection between 2009 and 2021 and who completed the Center for Epidemiologic Studies Depression Scale (CES-D) before and one year after surgery. Resection cavities were segmented on postoperative MRI scans. White matter disconnections were computed, the so-called disconnectome, to examine distant effects. Multivariable regression analysis was used to relate patient, tumor, and treatment characteristics to postoperative depression scores and changes after surgery. Lesion-symptom mapping was used to relate resection and disconnectome locations to these scores and changes. Results: The study included 83 patients. Before surgery, 25% of patients had depressive symptoms and one year after surgery 34%, which was not statistically different. Resections of gliomas in the right hemisphere were significantly associated with increased depression scores after surgery. A resection involving the left anterior temporal region was significantly associated with low postoperative depression scores. Disconnectome locations were not associated with either postoperative or change in depression scores. Conclusions: Resection locations affect depressive symptoms in glioma patients. This information may be useful for patient counseling.
- 16 December 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdae222
Open AccessImpact of resection location on depressive symptoms following glioma surgery
Background: Glioma surgery aims to maximize tumor removal while preserving functional integrity. Functional outcome usually focuses on neurological and neurocognitive functions, but surgery may also affect mood regulation. We determined the occurrence of depressive symptoms after surgery and investigated associated factors, including preoperative depressive symptoms and the location of the resection. Methods: We included a single-center retrospective cohort of patients with supratentorial diffuse glioma (WHO grade 2–4) who underwent first-time surgical resection between 2009 and 2021 and who completed the Center for Epidemiologic Studies Depression Scale (CES-D) before and one year after surgery. Resection cavities were segmented on postoperative MRI scans. White matter disconnections were computed, the so-called disconnectome, to examine distant effects. Multivariable regression analysis was used to relate patient, tumor, and treatment characteristics to postoperative depression scores and changes after surgery. Lesion-symptom mapping was used to relate resection and disconnectome locations to these scores and changes. Results: The study included 83 patients. Before surgery, 25% of patients had depressive symptoms and one year after surgery 34%, which was not statistically different. Resections of gliomas in the right hemisphere were significantly associated with increased depression scores after surgery. A resection involving the left anterior temporal region was significantly associated with low postoperative depression scores. Disconnectome locations were not associated with either postoperative or change in depression scores. Conclusions: Resection locations affect depressive symptoms in glioma patients. This information may be useful for patient counseling.
- Open Access
- 20 September 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (1) , 122-130
Baseline factors relating to depressive symptoms at one year postoperative in patients with diffuse glioma
Background: Depressive symptoms are common in patients with diffuse glioma, potentially reducing their quality of life. Understanding baseline factors associated with the development of depressive symptoms is important for psychoeducation and early intervention. This study investigates the associations of baseline patient- and tumor-related characteristics and depressive symptoms 1 year after surgery. Methods: We combined retrospective longitudinal datasets from Amsterdam UMC and Rigshospitalet Copenhagen. Several characteristics of patients and tumors were retrieved, in particular items of their mood and functioning status. Depression instruments were harmonized to the Patient-Reported Outcomes Measurement Information System Depression scale through previously developed item response theory. Functioning items were harmonized to the International Classification of Functioning, Disability, and Health (ICF) domains using linking methods published previously. We analyzed the associations of 25 baseline factors with depressive symptoms one year after surgery by multivariable stepwise backward linear regression models and verified model robustness using best subset selection. Results: We included 118 patients with diffuse glioma with a mean age of 48 years and a glioblastoma in 29%. Baseline depressive symptoms, lower ICF energy, and impaired ICF language functioning were associated with more depressive symptoms at follow-up in the multivariable model (R-squared: 0.379). Conclusions: We identified 3 key baseline factors associated with depressive symptoms one year after surgery. Clinically, our findings contribute to the comprehension of predictive factors for depressive symptoms, aiding healthcare providers and patients in understanding and possibly allowing for early intervention.
- 20 September 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (1) , 122-130
Open AccessBaseline factors relating to depressive symptoms at one year postoperative in patients with diffuse glioma
Background: Depressive symptoms are common in patients with diffuse glioma, potentially reducing their quality of life. Understanding baseline factors associated with the development of depressive symptoms is important for psychoeducation and early intervention. This study investigates the associations of baseline patient- and tumor-related characteristics and depressive symptoms 1 year after surgery. Methods: We combined retrospective longitudinal datasets from Amsterdam UMC and Rigshospitalet Copenhagen. Several characteristics of patients and tumors were retrieved, in particular items of their mood and functioning status. Depression instruments were harmonized to the Patient-Reported Outcomes Measurement Information System Depression scale through previously developed item response theory. Functioning items were harmonized to the International Classification of Functioning, Disability, and Health (ICF) domains using linking methods published previously. We analyzed the associations of 25 baseline factors with depressive symptoms one year after surgery by multivariable stepwise backward linear regression models and verified model robustness using best subset selection. Results: We included 118 patients with diffuse glioma with a mean age of 48 years and a glioblastoma in 29%. Baseline depressive symptoms, lower ICF energy, and impaired ICF language functioning were associated with more depressive symptoms at follow-up in the multivariable model (R-squared: 0.379). Conclusions: We identified 3 key baseline factors associated with depressive symptoms one year after surgery. Clinically, our findings contribute to the comprehension of predictive factors for depressive symptoms, aiding healthcare providers and patients in understanding and possibly allowing for early intervention.
- Open Access
- 11 July 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (7) , 853-864
Tumor location is associated with mood dysfunction in patients with diffuse glioma
Gliomas are primary brain tumors that can cause neuropsychiatric symptoms, including severe depressive symptoms (SDS; in 14%) and an absence of depressive symptoms (ADS; in 29%), determined by Center for Epidemiologic Studies Depression (CES-D) scores. We examined the association between both SDS and ADS and brain tumor location in 201 patients with diffuse glioma before surgery. Tumors and white matter disconnectomes did not relate to CES-D using sparse canonical correlation analysis. SDS were associated with tumors in the right corticospinal tract, fornix, and inferior fronto-occipital fasciculus and the left uncinate fasciculus, whereas ADS was associated with tumors in the left uncinate fasciculus and first segment of the superior longitudinal fasciculus and the right temporal cingulum and thalamus using Bayesian regression analyses. ADS occurs even more frequently in patients with diffuse glioma than does SDS, which is explained partly by tumor location. This research aids the understanding of gliomas and mood dysfunction in general.
- 11 July 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (7) , 853-864
Open AccessTumor location is associated with mood dysfunction in patients with diffuse glioma
Gliomas are primary brain tumors that can cause neuropsychiatric symptoms, including severe depressive symptoms (SDS; in 14%) and an absence of depressive symptoms (ADS; in 29%), determined by Center for Epidemiologic Studies Depression (CES-D) scores. We examined the association between both SDS and ADS and brain tumor location in 201 patients with diffuse glioma before surgery. Tumors and white matter disconnectomes did not relate to CES-D using sparse canonical correlation analysis. SDS were associated with tumors in the right corticospinal tract, fornix, and inferior fronto-occipital fasciculus and the left uncinate fasciculus, whereas ADS was associated with tumors in the left uncinate fasciculus and first segment of the superior longitudinal fasciculus and the right temporal cingulum and thalamus using Bayesian regression analyses. ADS occurs even more frequently in patients with diffuse glioma than does SDS, which is explained partly by tumor location. This research aids the understanding of gliomas and mood dysfunction in general.
- Open Access
- 1 February 2023
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 8 (1) , 41-55
Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
Background: Cannabinoids have been suggested to alleviate frequently experienced symptoms of reduced mental well-being such as anxiety and depression. Mental well-being is an important subdomain of health-related quality of life (HRQoL). Reducing symptoms and maintaining HRQoL are particularly important in malignant primary brain tumor patients, as treatment options are often noncurative and prognosis remains poor. These patients frequently report unprescribed cannabinoid use, presumably for symptom relieve. As studies on brain tumor patients specifically are lacking, we performed a meta-analysis of the current evidence on cannabinoid efficacy on HRQoL and mental well-being in oncological and neurological patients. Methods: We performed a systematic PubMed, PsychINFO, Embase, and Web of Science search according to PRISMA guidelines on August 2 and 3, 2021. We included randomized controlled trials (RCTs) that assessed the effects of tetrahydrocannabinol (THC) or cannabidiol (CBD) on general HRQoL and mental well-being. Pooled effect sizes were calculated using Hedges g. Risk of bias of included studies was assessed using Cochrane's Risk of Bias tool. Results: We included 17 studies: 4 in oncology and 13 in central nervous system (CNS) disease. Meta-analysis showed no effect of cannabinoids on general HRQoL ( g =−0.02 confidence interval [95% CI −0.11 to 0.06]; p =0.57) or mental well-being ( g =−0.02 [95% CI −0.16 to 0.13]; p =0.81). Conclusions: RCTs in patients with cancer or CNS disease showed no effect of cannabinoids on HRQoL or mental well-being. However, studies were clinically heterogeneous and since many glioma patients currently frequently use cannabinoids, future studies are necessary to evaluate its value in this specific population.
- 1 February 2023
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 8 (1) , 41-55
Open AccessCannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
Background: Cannabinoids have been suggested to alleviate frequently experienced symptoms of reduced mental well-being such as anxiety and depression. Mental well-being is an important subdomain of health-related quality of life (HRQoL). Reducing symptoms and maintaining HRQoL are particularly important in malignant primary brain tumor patients, as treatment options are often noncurative and prognosis remains poor. These patients frequently report unprescribed cannabinoid use, presumably for symptom relieve. As studies on brain tumor patients specifically are lacking, we performed a meta-analysis of the current evidence on cannabinoid efficacy on HRQoL and mental well-being in oncological and neurological patients. Methods: We performed a systematic PubMed, PsychINFO, Embase, and Web of Science search according to PRISMA guidelines on August 2 and 3, 2021. We included randomized controlled trials (RCTs) that assessed the effects of tetrahydrocannabinol (THC) or cannabidiol (CBD) on general HRQoL and mental well-being. Pooled effect sizes were calculated using Hedges g. Risk of bias of included studies was assessed using Cochrane's Risk of Bias tool. Results: We included 17 studies: 4 in oncology and 13 in central nervous system (CNS) disease. Meta-analysis showed no effect of cannabinoids on general HRQoL ( g =−0.02 confidence interval [95% CI −0.11 to 0.06]; p =0.57) or mental well-being ( g =−0.02 [95% CI −0.16 to 0.13]; p =0.81). Conclusions: RCTs in patients with cancer or CNS disease showed no effect of cannabinoids on HRQoL or mental well-being. However, studies were clinically heterogeneous and since many glioma patients currently frequently use cannabinoids, future studies are necessary to evaluate its value in this specific population.
- Open Access
Frequency and burden of potentially treatable symptoms in glioma patients with stable disease